GGrantIndex
← Search

PHASE I DOSE ESCALATION, SAFETY, TOLERABILITY OF TAS 103

$0M01FY2002RRNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Abstract

21 patients have completed the study and the data is being analyzed.

View original record on NIH RePORTER →